Next-Generation Off-the-Shelf CAR T-Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Thursday, July 10, 2025 1 min read
Key Takeaway: The article discusses a novel platform for off-the-shelf CAR T-cells aimed at treating autoimmune diseases without the need for conditioning chemotherapy. It highlights the potential for comprehensive elimination of aberrant effector cells. However, specific details about the platform's efficacy or clinical applications are not provided.
Price reaction · baseline $1.155 (2025-07-10T15:15:00.000Z) · hit during market hours · clean, no other FATE news in the window
day 0 close · peak
+0.4%
Market Sentiment Analysis
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.